Synapse - Restarting teclistamab and talquetamab after prolonged dose delay may not require re

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing Research Letter

Authors:	Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U. A.; Rajeeve, S.; Hashmi, H.; Patel, D.; Firestone, R.; Jurgens, E.; Miller, K.; Shah, G. L.; Scordo, M.; Landau, H. J.; Giralt, S. A.; Korde, N.; Usmani, S. Z.
Title:	Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
Keywords:	aged; major clinical study; overall survival; recommended drug dose; neurotoxicity; multiple myeloma; immunoglobulin; central nervous system; hospitalization; paracetamol; corticosteroid; drug substitution; pentamidine; diphenhydramine; cytokine release syndrome; tocilizumab; human; male; female; article; b cell maturation antigen; antibody drug conjugate; chimeric antigen receptor t-cell immunotherapy; teclistamab; relapsed refractory multiple myeloma; talquetamab; t cell depletion therapy
Journal Title:	Blood Advances
Volume:	9
Issue:	13
ISSN:	2473-9529
Publisher:	American Society of Hematology
Date Published:	2025-07-08
Start Page:	3331
End Page:	3335
Language:	English
DOI:	10.1182/bloodadvances.2024015344
PUBMED:	40048741
PROVIDER:	scopus
PMCID:	PMC12268624
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105009628585&doi=10.1182%2fbloodadvances.2024015344&partnerID=40&md5=0190c6cf3e7a82c19340022561723192
Notes:	Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding authors are Carlyn Rose Tan and Alice Wang -- Source: Scopus